Estados Unidos - inglés - NLM (National Library of Medicine)

cardinal health - varenicline tartrate (unii: 82269asb48) (varenicline - unii:w6hs99o8zo) - varenicline 0.5 mg

Estados Unidos - inglés - NLM (National Library of Medicine)

lake erie medical & surgical supply dba quality care products llc - varenicline tartrate (unii: 82269asb48) (varenicline - unii:w6hs99o8zo) - varenicline 0.5 mg

Australia - inglés - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - modafinil, quantity: 100 mg - tablet, uncoated - excipient ingredients: purified talc; aluminium magnesium silicate; lactose monohydrate; povidone; croscarmellose sodium; maize starch; magnesium stearate - modafinil is indicated: ? to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy; ? to treat excessive sleepiness associated with moderate to severe chronic shift work sleep disorder where nonpharmacological interventions are unsuccessful or inappropriate; ? as an adjunct to continuous positive airways pressure (cpap) in obstructive sleep apnoea/hypopnoea syndrome in order to improve wakefulness.

Austria - alemán - AGES (Agentur für Gesundheit und Ernährungssicherheit)

sanofi-aventis gmbh - enoxaparin natrium - enoxaparin

Australia - inglés - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - carboplatin, quantity: 10 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections - carboplatin is indicated in the treatment of ovarian cancer of epithelial origin and in second line therapy after other treatments have failed.

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

arrow generics limited - topiramate - capsule - 15 milligram

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

mcdowell pharmaceuticals - mirtazapine - orodispersible tablet - 15 milligram

Australia - inglés - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - itraconazole, quantity: 100 mg - capsule - excipient ingredients: hypromellose; macrogol 20000; sucrose; hydrolysed maize starch; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - itracap is indicated for use in adults for the treatment of: ? superficial dermatomycoses not responding to topical treatment. ? fungal keratitis which has failed to respond to topical treatment or where the disease is either progressing rapidly or is immediately sight threatening. ? pityriasis versicolor not responding to any other treatment. ? vulvovaginal candidiasis not responding to topical treatment. ? oral candidiasis in immunocompromised patients. ? onychomycosis caused by dermatophytes. ? systemic mycoses: - systemic aspergillosis, histoplasmosis, sporotrichosis. - treatment and maintenance therapy in aids patients with disseminated or chronic pulmonary histoplasmosis infection. - treatment of oropharyngeal and/or oesophageal candidiasis when first line systemic antifungal therapy is inappropriate or has proven ineffective. - treatment of non-invasive candidiasis in non-neutropenic patients when first-line systemic antifungal therapy is inappropriate or has proven ineffective. this may be due to underlying pathology, insensitivity of the pathogen or drug toxicity.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - itraconazole, quantity: 100 mg - capsule - excipient ingredients: hypromellose; macrogol 20000; sucrose; hydrolysed maize starch; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - itranox is indicated for use in adults for the treatment of: ? superficial dermatomycoses not responding to topical treatment. ? fungal keratitis which has failed to respond to topical treatment or where the disease is either progressing rapidly or is immediately sight threatening. ? pityriasis versicolor not responding to any other treatment. ? vulvovaginal candidiasis not responding to topical treatment. ? oral candidiasis in immunocompromised patients. ? onychomycosis caused by dermatophytes. ? systemic mycoses: - systemic aspergillosis, histoplasmosis, sporotrichosis. - treatment and maintenance therapy in aids patients with disseminated or chronic pulmonary histoplasmosis infection. - treatment of oropharyngeal and/or oesophageal candidiasis when first line systemic antifungal therapy is inappropriate or has proven ineffective. - treatment of non-invasive candidiasis in non-neutropenic patients when first-line systemic antifungal therapy is inappropriate or has proven ineffective. this may be due to underlying pathology, insensitivity of the pathogen or drug toxicity.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ramipril, quantity: 5 mg - tablet - excipient ingredients: microcrystalline cellulose; sodium stearylfumarate; hypromellose; pregelatinised maize starch; iron oxide yellow - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension.,post mi heart failure,prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day.,for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease.,for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.